National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Glycopyrronium bromide (Sialanar®) is indicated for symptomatic treatment of severe sialorrhoea (chronic pathological drooling) in children and adolescents aged 3 years and older with chronic neurological disorders

Rapid Review

Commenced Completed Outcome
07 March 2017 13 April 2017 Full pharmacoeconomic evaluation recommended at the submitted price

Updated June 2017

Following an update to the rapid review of Glycopyrronium bromide (Sialanar®), a full pharmacoeconomic assessment is not recommended.